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Neurodevelopmental aberrations influenced by neurotrophic factors are among the impor-
tant paradigms to understand schizophrenia pathogenesis. Among various neurotrophic
factors, Brain-Derived Neurotrophic Factor (BDNF) is strongly implicated by previous
research studies. Evaluating co-morbidity free, antipsychotic-naïve schizophrenia patients
for BDNF levels and examining the correlates of this factor with symptoms might facili-
tate elucidation of its pathogenetic role without confounds of potential influencing factors.
In this study, 59 co-morbidity free, antipsychotic-naïve schizophrenia patients were com-
pared with 60 healthy controls for serum BDNF levels. In addition, the relationship between
Schneiderian First Rank Symptoms (FRS) and BDNF level in patients was examined. As a
group, schizophrenia patients (28.8±11.7 ng/mL) had significantly lower serum BDNF than
healthy controls (34.9±8.2 ng/mL) after controlling for the potential confounding effects
of age and sex (F = 7.8; p=0.006). Further analyses revealed FRS status to have signifi-
cant effect on plasma BDNF after controlling for the potential confounding effects of age
and sex (F =4.5; p=0.01). Follow-up post hoc analyses revealed FRS(+) patients to have
significant deficit in plasma BDNF level in comparison with healthy controls (p=0.002);
however, FRS(−) patients did not differ from healthy controls (p=0.38). Our study observa-
tions add further support to the role for BDNF in schizophrenia pathogenesis and suggest
a potential novel link between deficient BDNF and FRS.
Keywords: schizophrenia, antipsychotic-naïve, BDNF, Schneiderian first rank symptoms
INTRODUCTION
Neurodevelopmental model postulates schizophrenia as a behav-
ioral outcome of an aberration in brain development processes
that begins long before the onset of clinical symptoms and is
caused by a combination of genetic and environmental factors (1).
Gene-environment interaction especially involving genetic factors
and obstetric complications have been put forth as one of the
important mechanisms that increase the risk toward schizophre-
nia (2). Specifically, the genetic factors that interact with obstet-
ric complications have been postulated to encompass hypoxia-
ischemia regulated genes and Brain-Derived Neurotrophic Factor
(BDNF) gene is one among them (2). Given the increasing empha-
sis on the role of neurotrophic factors in the neurodevelopmental
pathogenesis of schizophrenia (3), BDNF has attracted significant
attention in schizophrenia research studies.
The compelling role for BDNF in the pathogenesis of schizo-
phrenia is supported by various lines of evidence [see for reviews
(4, 5)]. BDNF, the most widely distributed neurotrophin in the
central nervous system, is highly expressed in brain regions that
are critically implicated in the pathogenesis of schizophrenia –
the prefrontal cortex and hippocampus (6). BDNF has been
demonstrated to interact with various neurotransmitter systems
that are implicated in schizophrenia, such as dopamine, glutamate,
serotonin, and GABA (7).
Post-mortem studies have reported decreased levels of BDNF
protein in the hippocampus (8) and prefrontal cortex (9) in brains
of schizophrenia patients. Furthermore, significantly decreased
cerebrospinal fluid (CSF) levels of BDNF have been documented
in antipsychotic-naïve, first episode psychosis patients (10). Inter-
estingly, Pillai et al. (10) also demonstrated a significant positive
correlation between the CSF and plasma BDNF protein levels sup-
porting the view that measurement of blood/plasma BDNF levels
reflect the brain tissue levels (11).
Peripheral level of BDNF in schizophrenia patients has been
evaluated in many studies (12). Though an earlier meta-analytic
evaluation of these study findings supported decreased peripheral
levels of BDNF in schizophrenia patients (12), further studies on
antipsychotic-naïve patients have been recommended by a recent
review (5) to avoid the potential confounding effects of antipsy-
chotic treatment. Apart from medication status, symptom profile
of schizophrenia patients is another important factor with which
BDNF level has been linked. Significant negative correlation has
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been reported between BDNF level and severity of positive symp-
toms in few studies (10, 13). In relation to this observation, it
is important to note that met-BDNF allele [the genotype that is
shown to be associated with reduced BDNF level (14)] has been
shown to be associated decreased volume (15), lower metabolic
ratios of N -acetyl aspartate and glutamate (16) of the hippocam-
pus, and as well as with reduced volume of the right inferior
parietal lobule (17) – the brain regions that are implicated in
the genesis of positive symptoms in schizophrenia (18). Inter-
estingly, the right inferior parietal lobule abnormalities has been
repeatedly shown to be associated with Schneiderian First Rank
Symptoms (FRS) in many studies (19–22). However, it has to be
acknowledged that the anatomical and pathophysiological basis
of positive symptoms and Schneiderian FRS are still very poorly
understood, and several brain regions other than those mentioned
above have been proposed to contribute to them. Since BDNF
has been reported to influence brain development until adoles-
cent/early adult period, it is plausible BDNF deficit might result in
reduced volumes/aberrations in these specific brain regions.
In this study, we evaluated serum BDNF in antipsychotic-naïve
schizophrenia patients (N = 59) in comparison with healthy con-
trols (N = 60). As reviewed above, very few studies that have
evaluated the symptom correlates of BDNF in schizophrenia sug-
gest significant negative correlation between BDNF and positive
symptoms (10, 13) as well as link between BDNF and certain brain
regions that are shown to underlie the genesis of FRS (17). To
ascertain this relationship further, in this study, we have eval-
uated antipsychotic-naïve schizophrenia patients in comparison
with healthy controls for serum BDNF; also, we concurrently
assessed the Schneiderian FRS in patients. We hypothesized that
schizophrenia patients with FRS will show deficient BDNF level
in comparison with healthy controls while those without FRS will
not differ significantly.
MATERIALS AND METHODS
Patients attending the clinical services of the National Institute of
Mental Health and Neurosciences (India), who fulfilled DSM-IV
criteria for schizophrenia and were never treated with any psy-
chotropic medications including antipsychotics and not having
substance abuse [n= 59; age= 31 males], were examined in this
study. The diagnosis of schizophrenia was established using Mini
International Neuropsychiatric Interview Plus (23), which was
confirmed by another psychiatrist through an independent clinical
interview. The details related to illness onset and antipsychotic-
naïve status as well as substance use was carefully ascertained
by reliable information obtained from at least one reliable adult
relative (first-degree). Psychotic symptoms were assessed using
Scale for Assessment of Positive Symptoms (SAPS) and Scale for
Assessment of Negative Symptoms (SANS).
First Rank Symptoms were examined using a comprehensive
semi-structured interview (22) as per the established descriptions
(24); these 11 symptoms described by Mellor included the follow-
ing: audible thoughts, voices arguing, voices commenting, thought
insertion, thought withdrawal, thought broadcast, made feelings,
made impulses, made volitions, somatic passivity, and delusional
percept (24). In addition, the presence of FRS was independently
ascertained by a qualified psychiatrist by a comprehensive mental
status examination. Depending upon the presence of at least one
FRS, schizophrenia patients were classified into those with FRS
[FRS(+); N = 36] and those without FRS [FRS(−); N = 23].
Healthy controls (n= 60) (age= 26.4± 4.7 years; 29 males),
who volunteered for study, were screened to rule out any psychi-
atric diagnosis using the MINI as well as a comprehensive mental
status examination. None of the controls had family history of
psychiatric disorder in first-degree relatives.
Patients and controls did not have features suggestive of alco-
hol abuse/dependence. History related to substance use in patients
was carefully ascertained by reliable information obtained from at
least one reliable adult relative (first-degree). None used stimulant
or opiate drug. None had history or clinical feature suggestive of
neurological/medical disorder. None had abnormal movements
as assessed by Abnormal Involuntary Movements Scale. Physi-
cal activity status of all study subjects was quantified using the
Simplified Indian Diabetes Risk Score. Clinical assessments and
blood sample collection were performed on the same day before
starting antipsychotics. After complete description of study to the
subjects, written informed consent was obtained. The Institute’s
ethics committee approved the study.
Blood samples were collected from all subjects between 08:00
and 09:00 h (a.m.) after 12-h overnight fast. Blood was drawn
from an ante-cubital vein into vacutainer tubes (Becton and Dick-
inson, USA). Using a serum separator tube (SST™ II Advance,
BD Vacutainer®, NJ, USA) samples were collected, mixed well
by inversion, and allowed to clot for 30 min before centrifuga-
tion for 15 min at 1000× g. Serum was separated, aliquoted, and
stored at −80° C. Quantitative sandwich enzyme immunoassay
of serum BDNF was done using commercially available ELISA
kit with sensitivity <20 pg/mL (R&D Systems, MN, USA). All
samples were coded and analyzed by the same investigator, who
was blind to the clinical situation. Serum was examined instead
of plasma in order to avoid irreproducible results due to BDNF
contained in platelets and released by platelet activation. Briefly,
samples (diluted 20-fold) and standards (concentration 62.5–
4000 pg/mL) are incubated in 96-well microplate pre-coated with
BDNF specific monoclonal antibody followed by incubation with
enzyme-linked monoclonal antibody specific for BDNF. After
three washes, the reaction was developed with tetramethylbenzi-
dine (TMB) and stopped with sulfuric acid. The absorbances were
measured with an automated microplate reader at 450 nm (cor-
rected for optical imperfections at 620 nm) [The standard curves
of the ELISA assays and the subject-wise BDNF values are pro-
vided in the Data Sheet S1 and S2 in Supplementary Material
respectively].
Data analysis was performed using the SPSS-11.0 using
the following statistics after ascertaining the normality of the
data distribution: Student’s t -test (two-tailed), chi-square test,
analysis of variance (ANOVA), and analysis of covariance
(ANCOVA).
RESULTS
The characteristics of the study subjects are given in Table 1.
FRS(+) patients, FRS(−) patients and healthy controls, as a group,
did not differ significantly in sex ratio and physical activity scores
(p> 0.3). Both FRS(+) and FRS(−) patients were significantly
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Table 1 | Comparative profile of schizophrenia patients with and without FRS and healthy controls.
Characteristics FRS(+) FRS(−) Controls Statistic p
N 36 23 60
Age (years)* 31.7±6.8 30.4±7.5 26.4±4.7 F =12.2 <0.001
Sex ratio (M:F)$ 17:19 14:09 29:31 χ2=1.3 0.53
Age at onset of psychosis (years)# 28.1±7.6 29.4±7.1 – t =0.6 0.52
Duration of untreated psychosis (months)# 28.1±27.0 29.2±41.3 – t =0.1 0.52
Physical activity score* 24.2±6.5 25.7±7.3 23.0±9.1 F =0.9 0.39
BDNF (ng/mL)** 27.3±11.8 31.1±11.5 34.9±8.2 F =4.5 0.01
*ANOVA; $chi-square test; # independent samples t-test; **ANCOVA controlling for potential confounding effects of age and sex.
older than healthy controls; however, between them, FRS(+) and
FRS(−) patients did not significantly differ in age. As a group,
schizophrenia patients (28.8± 11.7 ng/mL) had significantly lower
serum BDNF than healthy controls (34.9± 8.2 ng/mL) after con-
trolling for the potential confounding effects of age and sex
(F = 7.8; df= 117; p= 0.006). Further analyses revealed FRS status
to have significant effect on plasma BDNF after controlling for the
potential confounding effects of age and sex (F = 4.5; df= 6, 112;
p= 0.01) (Table 1; Figure 1). Follow-up post hoc analyses revealed
FRS(+) patients to have significant deficit in plasma BDNF level in
comparison with healthy controls (p= 0.002); however, FRS(−)
patients did not differ from healthy controls (p= 0.38). There was
no significant effect of sex of the subject on plasma BDNF in this
analysis. SAPS (r = 0.01; p= 0.93) and SANS (r = 0.06; p= 0.69)
total scores did not show any significant correlation with serum
BDNF level.
DISCUSSION
Our study finding of significantly deficient serum BDNF level
in antipsychotic-naïve schizophrenia patients replicates previous
similar reports (13, 25–27). The deficient BDNF level seems to be
predominantly contributed by schizophrenia patients with FRS; to
the best of our knowledge, this is the first time report of relation-
ship between FRS and deficient BDNF in schizophrenia. Some of
the previous studies have demonstrated significant negative corre-
lation between BDNF level and severity of positive symptoms (10,
13). In our study, we did not find any significant correlation total
positive symptom score; however, in comparison with healthy con-
trols, patient with FRS showed significantly deficient BDNF level
whereas those without FRS did not differ significantly. The FRS
assessed in this study encompassed audible thoughts, voices argu-
ing, voices commenting, thought insertion, thought withdrawal,
thought broadcast, made feelings, made impulses, made volitions,
somatic passivity, and delusional percept – these symptoms are
unified by the striking breach in one’s ability ability to differen-
tiate “self” from “non-self.” It is possible that the component of
delusions and hallucinations as emphasized by the FRS might be
linked with the BDNF and this might explain the heterogene-
ity in previous reports. Moreover, in this context, it has to be
acknowledged that a correlation between BDNF and FRS does not
imply causality. The possibility that third factors may be involved
should be recognized, while identifying these factors may not be
possible.
FIGURE 1 | It shows comparative profile of serum BDNF levels in
FRS(+) patients (N = 36), FRS(−) (N =23), and healthy controls
(N =60).
Imaging studies examining the neural correlates of FRS
in schizophrenia patients have demonstrated relationship with
abnormalities involving parietal cortex (19, 22), parahippocampal
gyrus, and posterior cingulate cortex (28). It is interesting to
note that these brain regions have been shown to be affected
by BDNF. For example, healthy 66Met allele carriers had sig-
nificantly deficient inferior parietal lobule (17) and parahip-
pocampal gyrus volumes (29). In a large study examining 258
adult twins and their non-twin siblings, it was demonstrated
that BDNF polymorphism significantly contributed to the vari-
ation in white matter integrity in the posterior cingulate gyrus
by accounting for around 90–95% of total variance in fractional
anisotropy (30).
It is noteworthy that 66Met allele has been associated with
schizophrenia risk [see for reviews (4, 5)]. Moreover, 66Met allele is
associated with decreased levels of BDNF (31). Thus, it is possible
that deficient levels of BDNF might have led to aberrations involv-
ing critical brain regions (like inferior parietal lobule, parahip-
pocampal, and posterior cingulate gyri) resulting in genesis of
FRS in schizophrenia. Our study observations offer preliminary
support to this hypothesis.
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Examination of antipsychotic-naïve schizophrenia patients,
ensuring the uniform timing of collection of blood sample
matches with some of the methodological strengths of the previous
similar studies. In addition, we matched the patients and controls
for physical activity status which could be another potential con-
founding factor. Significant difference in age between patients and
controls can be construed as a potential limitation, since increasing
age has been associated with decreased BDNF level. However, the
significance of BDNF difference persisted even after controlling
for age; moreover, we did not observe any significant correlation
between age and BDNF level in this study. Measuring BDNF level
in serum than CSF might be considered as another limitation
especially since we attempt to infer the peripheral BDNF levels as
indicative of brain levels; nonetheless, it is important to note that
previous reports have supported this assumption (10, 32).
In summary, our study observations add further support to
the role for BDNF in schizophrenia pathogenesis. These findings
also support the possibility that the BDNF changes in early life
that perhaps render individuals more susceptible to schizophrenia
also continue into adulthood with adverse impact on neurodevel-
opmental trajectory. In addition, a potential novel link between
deficient BDNF and Schneiderian FRS is suggested by these find-
ings. This needs to be evaluated further with concurrent analyses
involving genotype as well as peripheral level of BDNF along with
brain imaging studies in the same cohort of schizophrenia patients.
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